A week after a study showed that Vytorin is no more effective in reducing cholesterol than the company’s generic equivalent, Merck and Schering-Plough withdrew their direct-to-consumer marketing ads. Vytorin, a combination of Zetia and Merck’s Zocor, lost patent protection in 2006. The marketing campaign was a familiar one to television viewers and was dubbed “food and family” depicting in a light-hearted fashion how heredity and eating habits can affect a person’s cholesterol. However, the marketing campaign never mentioned any risks or the fact that its generic equivalent was at the very least, as effective as the expensive Vytorin.
For more information on this subject, please refer to the section on Drugs, Medical Devices and Implants.
Admitted to practice law in all federal multidistrict litigation courts, the California State Bar and the Florida Bar. His philosophy is to provide aggressive, quality representations and seek fair compensation for individuals and their families who have suffered injury, death, or sexual abuse.
Comments for this article are closed.